San Francisco startup Composition Therapeutics is also focusing on an oral, at the time-every day GLP-1 drug identified as GSBR-1290—the drug surpassed Wall Road’s anticipations in June every time a mid-stage study confirmed typical weight loss of about six% and it options to start out One more mid-phase demo to the top of the year—that found